Dry powder inhalations in the treatment of pulmonary tuberculosis
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Presentation
- By: MISRA, Amit (CSIR-Central Drug Research Institute, Pharmaceutics Division, Lucknow, India)
Background: Although tuberculosis (TB) is primarily a lung disease, standard chemotherapy requires oral administration of a long duration regimen. Significant adverse effects are often seen.
Aim: We wanted a dry powder inhalation (DPI) that could target drugs to lung macrophages, and also stimulate these cells to overcome the state of alternative.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.